<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143622</url>
  </required_header>
  <id_info>
    <org_study_id>CLJM716X2104</org_study_id>
    <nct_id>NCT02143622</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients</brief_title>
  <official_title>A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects
      in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Target lesion change compared to baseline in patients, per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the preliminary anti-tumor activity of LJM716 in combination. Change in target lesion measurements, from baseline as per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)</measure>
    <time_frame>35 days</time_frame>
    <description>The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose of LJM716 in combination with cetuximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Percentage of Patients with an Objective Overall Response (OOR) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Patients with an Objective Overall Response (OOR) were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed by imaging, as pr RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the LJM716- cetuximab combination</measure>
    <time_frame>6 months</time_frame>
    <description>This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration versus time profiles blood PK parameters of LJM716 and cetuximab concentration</measure>
    <time_frame>6 months</time_frame>
    <description>blood concentration versus time profiles blood PK parameters will be used to characterize the PK profiles of LJM716 and cetuximab concentration when used in combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR), per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>BOR will be used to further assess the anti-tumor activity of LJM716-cetuximab combination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of response will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) per RECIST 1.1</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Progression free survival will be used to further assess the anti-tumor activity of LJM716-cetuximab combination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LJM716</intervention_name>
    <description>antibody</description>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>antibody</description>
    <arm_group_label>LJM716+cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Most recent regimen contains both platinum and cetuximab (Phase II, group B).

          -  ECOG Performance Status (PS) ≤ 2.

          -  Recovery from all AEs of previous anti-cancer therapies, to baseline or to CTCAE Grade
             ≤ 1, except for alopecia.

          -  Measurable disease as determined by RECIST v1.1.

        Exclusion Criteria:

          -  Previous anti-HER3 antibody treatment.

          -  Symptomatic brain metastasis.

          -  Prior systemic anti-cancer treatment, within a period of time that is shorter than the
             cycle length used for that treatment prior to starting study treatment.

          -  Prior anaphylactic or other severe infusion reaction to human immunoglobulin or
             antibody formulations.

          -  Inadequate end organ function.

          -  Ongoing diarrhea CTCAE Grade ≥ 2. Other protocol-defined inclusion/exclusion criteria
             may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

